• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Establishment Labs Holdings Inc.

    4/24/26 4:36:11 PM ET
    $ESTA
    Industrial Specialties
    Health Care
    Get the next $ESTA alert in real time by email
    DEFA14A 1 estasupplementalproxyapril.htm DEFA14A Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 14A
    PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE
    SECURITIES EXCHANGE ACT OF 1934
    Filed by the Registrant x
    Filed by a party other than the Registrant ¨
    Check the appropriate box:
    ¨    Preliminary Proxy Statement
    ¨    Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2))
    ¨    Definitive Proxy Statement
    x    Definitive Additional Materials
    ¨    Soliciting Material under §240.14a‑12

    Establishment Labs Holdings Inc.
    (Name of Registrant as Specified In Its Charter)

    Payment of Filing Fee (Check all boxes that apply):
    x    No fee required
    ¨    Fee paid previously with preliminary materials
    ¨    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a‑6(i)(1) and 0‑11




    ESTABLISHMENT LABS HOLDINGS INC.
    SUPPLEMENT TO PROXY STATEMENT
    FOR 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS
    To be held at 1:00 p.m., Eastern Time, on Friday, May 22, 2026
    This proxy statement supplement, dated April 24, 2026 (this “Supplement”), supplements the definitive proxy statement on Schedule 14A of Establishment Labs Holdings Inc. (the “Company”), dated April 10, 2026 (the “Proxy Statement”), for the Company’s Annual Meeting of Shareholders to be held on May 22, 2026 (the “Annual Meeting”).
    THIS SUPPLEMENT SHOULD BE READ IN CONJUNCTION WITH THE PROXY STATEMENT. EXCEPT AS SPECIFICALLY SUPPLEMENTED BY THE INFORMATION CONTAINED HEREIN, THIS SUPPLEMENT DOES NOT MODIFY ANY OTHER INFORMATION SET FORTH IN THE PROXY STATEMENT.

    Explanatory Note
    The Company is filing this proxy supplement to correct a typographical error contained in the “2025 Non-Employee Director Compensation” table included in the Non-Employee Director Compensation section of the Proxy Statement, which incorrectly reported the stock awards that Juan José Chacón Quirós, Ann Custin, Leslie Gillin, Nicholas Lewin, Edward J. Schutter, and Bryan Slotkin received as $374,946. The correct amount of stock awards that Juan José Chacón Quirós received is $499,975 and that Ann Custin, Leslie Gillin, Nicholas Lewin, Edward J. Schutter, and Bryan Slotkin received is $124,984, which also results in a change to Mr. Quirós, Ms. Custin, Ms. Gillin, Mr. Lewin, Mr. Schutter, and Mr. Slotkin’s total compensation amounts. Accordingly, the Proxy Statement disclosure under the heading Non-Employee Director Compensation is amended and replaced in its entirety with the following disclosure.
    2025 NON-EMPLOYEE DIRECTOR COMPENSATION
    The following table presents the total compensation for each person who served as a non-employee member of our Board during 2025:
    Name
    Fees Earned or Paid in Cash(1)
    Stock Awards (2) (3)
    Option Awards (2) (3)
    Total
    Juan José Chacón Quirós (4)
    $33,333 $499,975 $374,991 $908,299 
    Dennis Condon (5)
    $13,750 $— $— $13,750 
    Ann Custin$82,444 $124,984 $— $207,428 
    Leslie Gillin$67,500 $124,984 $— $192,484 
    Nicholas Lewin (6)
    $100,000 $124,984 $906,223 $1,131,207 
    Edward J. Schutter$75,000 $124,984 $— $199,984 
    Bryan Slotkin$65,000 $124,984 $— $189,984 
    (1)    In 2025, all directors except for Mr. Chacón Quirós elected to receive their quarterly fees in shares. The amounts listed reflect the total fair value of the shares as granted, which is based on the stock value at the end of each quarter and the total fees in cash earned each quarter by each director.
    (2)    The aggregate grant date fair value of these awards was computed in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718 and excludes the effects of estimated forfeitures. The reported award values have been determined using the assumptions described in Note 10 to the Consolidated Financial Statements included in our 2025 Annual Report.
    (3)    The following chart sets forth the number of outstanding awarded restricted stock units (unvested) and stock options (unexercised) held by each non-employee director as of December 31, 2025. For Mr. Chacón Quirós, the amounts reported include all of his outstanding equity awards, whether granted in connection with his services as an employee or non-employee director.



    Name
    Outstanding Restricted Stock Units (7)
    Outstanding Stock Options
    Juan José Chacón Quirós
    30,209 197,130 
    Dennis Condon
    — 24,890 
    Ann Custin3,413 12,000 
    Leslie Gillin3,413 12,000 
    Nicholas Lewin
    31,169 93,856 
    Edward J. Schutter3,413 66,780 
    Bryan Slotkin3,413 12,000 
    (4)    Mr. Chacón Quirós formally terminated his non-director employment with the Company effective April 30, 2025. For Mr. Chacón Quirós, the amount reported in the Option Awards column includes the May 2025 grant for 14,906 stock options with an exercise price of $36.46 and 10,285 restricted stock units granted in consideration for advisory and advocacy services he performs for the Company in addition to his service as a non-employee director. This grant will vest over four years upon award. The May 23, 2025 grant for 3,413 restricted share units was granted for his services as a director. The executive compensation tables that follow describe and quantify Mr. Chacón Quirós compensation as our Chief Executive Officer, as a non-employee director and consultant.
    (5)    Mr. Condon served on the Board until his passing in January 2025.
    (6)    For Mr. Lewin, the amount reported in the Option Awards column includes a May 2025 grant for 36,027 stock options with an exercise price of $36.46 granted in consideration for consulting services he performs for the Company in addition to his service as a non-employee director. This grant will vest over four years upon award.
    (7)    For Mr. Lewin, the outstanding restricted stock units include a performance-based award granted in May 2023 for 27,756 shares vesting based on achievement of certain market conditions and continuing services for the Company.

    Voting Matters
    Please note that any proxy or voting instructions you have submitted for the Annual Meeting are still valid and will be used to vote your shares at the Annual Meeting. If you have already submitted your vote, you do not need to take any further action unless you intend to change or revoke your previous proxy or voting instructions. Information on how to vote your shares and how to change your vote or revoke your proxy or voting instructions is contained in the Proxy Statement. The Company urges shareholders to vote their shares prior to the Annual Meeting by using one of the methods described in the Proxy Statement.

    Get the next $ESTA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ESTA

    DatePrice TargetRatingAnalyst
    8/20/2025$60.00Buy
    Canaccord Genuity
    5/16/2025$62.00Buy
    BTIG Research
    5/14/2025$48.00Hold → Buy
    Needham
    4/14/2025Hold
    Needham
    5/22/2024$60.00Buy → Neutral
    Citigroup
    8/31/2023$75.00Overweight
    JP Morgan
    6/29/2023$79.00Buy
    Citigroup
    10/14/2022$90.00Overweight
    Stephens
    More analyst ratings

    $ESTA
    SEC Filings

    View All

    SEC Form DEFA14A filed by Establishment Labs Holdings Inc.

    DEFA14A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)

    4/24/26 4:36:11 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    SEC Form DEFA14A filed by Establishment Labs Holdings Inc.

    DEFA14A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)

    4/10/26 4:04:55 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    SEC Form DEF 14A filed by Establishment Labs Holdings Inc.

    DEF 14A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)

    4/10/26 4:04:19 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    $ESTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Establishment Labs® to Announce First Quarter 2026 Financial Results on May 6

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2026, before the market opens on Wednesday, May 6, 2026, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, Dial: 877-407-8037 (US & Canada) +1 201-689-8037 (international). The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.establishmentlabs.com. About Establishment Labs Est

    4/23/26 8:00:00 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Establishment Labs® Surpasses More Than Five Million Motiva® Devices in Market

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that it has surpassed more than five million Motiva devices in market. This milestone underscores the company's long‑standing commitment to science‑based innovation and reflects sustained global adoption of Motiva's portfolio of breast aesthetics and reconstruction solutions across more than 100 countries worldwide. "Surpassing five million Motiva devices is another milestone for our company, and a clear reflection that our investment in bringing better technology and procedures to mar

    4/7/26 8:00:00 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Establishment Labs Announces Leadership Transition to Support Next Phase of Growth

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced a strategic leadership transition of Raj Denhoy, current Chief Financial Officer to Senior Vice President, Global Strategy, and the appointment of Cassandra "Sandra" Harris to Senior Vice President and Chief Financial Officer, effective March 9, 2026. "Over the past few years, we have been focused on driving efficient execution and scalability. With the company well positioned for its next chapter of growth, we are creating additional leadership capacity to maintain operational momentum

    2/24/26 8:00:00 AM ET
    $ESTA
    $GCO
    Industrial Specialties
    Health Care
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    $ESTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chacon Quiros Juan Jose

    4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

    4/16/26 4:05:31 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    Amendment: SEC Form 4 filed by Caldini Filippo

    4/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

    4/8/26 5:38:58 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Schutter Edward J

    4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

    4/2/26 6:24:25 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    $ESTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lewin Nicholas Sheridan bought $98,410 worth of shares (2,600 units at $37.85) (SEC Form 4)

    4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

    8/14/25 10:58:27 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Director Lewin Nicholas Sheridan bought $78,880 worth of shares (2,300 units at $34.30) (SEC Form 4)

    4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

    8/13/25 11:02:28 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Amendment: Chief Executive Officer Caldini Filippo bought $100,320 worth of shares (2,850 units at $35.20), increasing direct ownership by 9% to 35,245 units (SEC Form 4)

    4/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

    8/11/25 4:02:37 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    $ESTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Establishment Labs with a new price target

    Canaccord Genuity initiated coverage of Establishment Labs with a rating of Buy and set a new price target of $60.00

    8/20/25 8:52:36 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    BTIG Research initiated coverage on Establishment Labs with a new price target

    BTIG Research initiated coverage of Establishment Labs with a rating of Buy and set a new price target of $62.00

    5/16/25 8:05:11 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Establishment Labs upgraded by Needham with a new price target

    Needham upgraded Establishment Labs from Hold to Buy and set a new price target of $48.00

    5/14/25 8:49:26 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    $ESTA
    Leadership Updates

    Live Leadership Updates

    View All

    Establishment Labs Announces Leadership Transition to Support Next Phase of Growth

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced a strategic leadership transition of Raj Denhoy, current Chief Financial Officer to Senior Vice President, Global Strategy, and the appointment of Cassandra "Sandra" Harris to Senior Vice President and Chief Financial Officer, effective March 9, 2026. "Over the past few years, we have been focused on driving efficient execution and scalability. With the company well positioned for its next chapter of growth, we are creating additional leadership capacity to maintain operational momentum

    2/24/26 8:00:00 AM ET
    $ESTA
    $GCO
    Industrial Specialties
    Health Care
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Establishment Labs Publishes 15 Years of Motiva Data in 2025 Post-Market Surveillance Report

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced publication of its 2025 Post-Market Surveillance (PMS) Report. The report is being released ahead of the annual meeting of the American Society of Plastic Surgeons held October 9-12 in New Orleans. "Publishing our PMS report every year since the launch of Motiva in 2010 shows our dedication to accountability and transparency," said Peter Caldini, Establishment Labs Chief Executive Officer. "No other company in our industry publishes this level of information on an annual basis, and I would enc

    10/9/25 8:00:00 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Establishment Labs Appoints Peter Caldini as Chief Executive Officer

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today the appointment of Peter Caldini as Chief Executive Officer effective May 7, 2025. Mr. Caldini has served as Interim CEO since March 1, 2025, when Establishment Labs' Founder and previous CEO Juan José Chacón-Quirós retired from the role. "After an extensive search process, it was clear that with his deep operational, commercial, and financial skills, Peter is the ideal person to lead Establishment Labs," commented Nick Lewin, Chairman of the Board of Establishment Labs. "We have a vision

    5/7/25 4:00:00 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    $ESTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Establishment Labs Holdings Inc.

    SC 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)

    11/12/24 12:54:20 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by Establishment Labs Holdings Inc.

    SC 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)

    11/12/24 9:03:38 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Establishment Labs Holdings Inc. (Amendment)

    SC 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)

    2/14/24 4:51:40 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    $ESTA
    Financials

    Live finance-specific insights

    View All

    Establishment Labs® to Announce First Quarter 2026 Financial Results on May 6

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2026, before the market opens on Wednesday, May 6, 2026, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, Dial: 877-407-8037 (US & Canada) +1 201-689-8037 (international). The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.establishmentlabs.com. About Establishment Labs Est

    4/23/26 8:00:00 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Establishment Labs Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the fourth quarter and full year ended December 31, 2025 and provided 2026 guidance. Fourth Quarter Highlights and Outlook Fourth quarter revenue of $64.6 million, an increase of 45.2% from the year-ago period. 2025 revenue of $211.1 million, an increase of 27.2% over 2024. Motiva U.S. revenue in the fourth quarter of $17.3 million, and full year U.S. revenue of $45.6 million. Fourth quarter net loss from operations of $3.9 million, a 79% reduction compa

    2/24/26 8:00:00 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Establishment Labs to Announce Fourth Quarter 2025 Financial Results on February 24

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended December 31, 2025, before the market opens on Tuesday, February 24, 2026, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or +1 (201) 689-8037 (International) and use conference ID number 13758679. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.

    2/10/26 8:00:00 AM ET
    $ESTA
    Industrial Specialties
    Health Care